These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 11307783)

  • 41. [Brugada syndrome].
    Bébarová M
    Vnitr Lek; 2011 Jun; 57(6):551-60. PubMed ID: 21751541
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Brugada syndrome: in search of a genotype-phenotype relationship.
    Smits JP; Wilde AA
    Herzschrittmacherther Elektrophysiol; 2002 Sep; 13(3):142-8. PubMed ID: 24535448
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Genetic analysis of Brugada syndrome and congenital long-QT syndrome type 3 in the Chinese.
    Liang P; Liu W; Li C; Tao W; Li L; Hu D
    J Cardiovasc Dis Res; 2010 Apr; 1(2):69-74. PubMed ID: 20877689
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Screening for, and management of, possible arrhythmogenic syndromes (channelopathies/ion channel diseases).
    Svendsen JH; Geelen P;
    Europace; 2010 May; 12(5):741-2. PubMed ID: 20421225
    [TBL] [Abstract][Full Text] [Related]  

  • 45. UltraRapid communications : vascular superoxide production by NAD(P)H OxidaseAssociation with endothelial dysfunction and clinical risk factors.
    Guzik TJ; West NE; Black E; McDonald D; Ratnatunga C; Pillai R; Channon KM
    Circ Res; 2000 May; 86(9):1008. PubMed ID: 10807875
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Gene specific therapy for cardiac disease: the case of long QT syndrome.
    Priori SG
    Rev Port Cardiol; 1998 Nov; 17 Suppl 3():III27-38. PubMed ID: 9857743
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Defining candidate drug characteristics for Long-QT (LQT3) syndrome.
    Tveito A; Lines GT; Li P; McCulloch A
    Math Biosci Eng; 2011 Jul; 8(3):861-73. PubMed ID: 21675815
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Brugada and short QT syndromes.
    Triedman JK
    Pacing Clin Electrophysiol; 2009 Jul; 32 Suppl 2():S58-62. PubMed ID: 19602164
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [QT syndrome: new diagnostic possibilities].
    Lewalter T; Englisch S; Jahr S; Schumacher B; Jung W; Hesch RD; Lüderitz B
    Z Kardiol; 1998 Jul; 87(7):517-21. PubMed ID: 9744062
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Catecholamines in children with congenital long QT syndrome and Brugada syndrome.
    Shimizu W; Kamakura S
    J Electrocardiol; 2001; 34 Suppl():173-5. PubMed ID: 11781952
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Purkinje system hyperexcitability and ventricular arrhythmia risk in type 3 long QT syndrome.
    Barake W; Giudicessi JR; Asirvatham SJ; Ackerman MJ
    Heart Rhythm; 2020 Oct; 17(10):1768-1776. PubMed ID: 32454217
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sudden cardiac arrest due to a single sodium channel mutation producing a mixed phenotype of Brugada and Long QT3 syndromes.
    Lakshmanadoss U; Mertens A; Gallagher M; Kutinsky I; Williamson B
    Indian Pacing Electrophysiol J; 2016; 16(2):66-69. PubMed ID: 27676163
    [TBL] [Abstract][Full Text] [Related]  

  • 53. SCN5A mutations associated with overlap phenotype of long QT syndrome type 3 and Brugada syndrome.
    Nakaya H
    Circ J; 2014; 78(5):1061-2. PubMed ID: 24694743
    [No Abstract]   [Full Text] [Related]  

  • 54. Flecainide, a therapeutic option in a patient with long QT syndrome type 3 caused by the heterozygous V411M mutation in the SCN5A gene.
    Carrasco JI; Izquierdo I; Medina P; Arnau MÁ; Salvador A; Zorio E
    Rev Esp Cardiol (Engl Ed); 2012 Nov; 65(11):1058-9. PubMed ID: 22721569
    [No Abstract]   [Full Text] [Related]  

  • 55. Role of chronic continuous intravenous lidocaine in the clinical management of patients with malignant type 3 long QT syndrome.
    Bains S; Lador A; Neves R; Bos JM; Giudicessi JR; Cannon BC; Ackerman MJ
    Heart Rhythm; 2022 Jan; 19(1):81-87. PubMed ID: 34537410
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Genetics of ion-channel disorders.
    Cerrone M; Napolitano C; Priori SG
    Curr Opin Cardiol; 2012 May; 27(3):242-52. PubMed ID: 22450718
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Tale of 2 Diseases: The History of Long-QT Syndrome and Brugada Syndrome.
    Havakuk O; Viskin S
    J Am Coll Cardiol; 2016 Jan; 67(1):100-8. PubMed ID: 26764071
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Syncope in Hereditary Arrhythmogenic Syndromes.
    Adler A; Viskin S
    Cardiol Clin; 2015 Aug; 33(3):433-40. PubMed ID: 26115829
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Beyond the One Gene-One Disease Paradigm: Complex Genetics and Pleiotropy in Inheritable Cardiac Disorders.
    Cerrone M; Remme CA; Tadros R; Bezzina CR; Delmar M
    Circulation; 2019 Aug; 140(7):595-610. PubMed ID: 31403841
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Recent advances in understanding the mechanisms, diagnosis and treatment of congenital and acquired long QT syndrome.
    Sra J; Akhtar M
    Indian Heart J; 1996; 48(6):639-51. PubMed ID: 9062011
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.